Analysts predict that Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) will announce earnings per share (EPS) of ($0.06) for the current quarter, according to Zacks. Zero analysts have made estimates for Citius Pharmaceuticals’ earnings. Citius Pharmaceuticals posted earnings per share of ($0.15) during the same quarter last year, which indicates a positive year-over-year growth rate of 60%. The company is scheduled to report its next quarterly earnings results on Thursday, February 10th.
According to Zacks, analysts expect that Citius Pharmaceuticals will report full-year earnings of ($0.26) per share for the current fiscal year, with EPS estimates ranging from ($0.36) to ($0.15). For the next fiscal year, analysts expect that the company will report earnings of $0.31 per share, with EPS estimates ranging from $0.21 to $0.41. Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Citius Pharmaceuticals.
Citius Pharmaceuticals (NASDAQ:CTXR) last announced its earnings results on Wednesday, December 15th. The company reported ($0.03) EPS for the quarter, hitting the consensus estimate of ($0.03).
A number of equities analysts recently issued reports on CTXR shares. HC Wainwright upped their price objective on shares of Citius Pharmaceuticals from $4.00 to $6.00 and gave the stock a “buy” rating in a research report on Tuesday, January 18th. Zacks Investment Research cut shares of Citius Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 20th. Finally, Maxim Group assumed coverage on shares of Citius Pharmaceuticals in a research report on Tuesday, November 30th. They set a “buy” rating and a $4.00 price objective for the company.
There aren’t many days left on the calendar… and yet the global semiconductor market grew to $466.2 billion – in spite of the pandemic.
Better still, the chip shortage has created huge opportunities for recurring success.
These four tech companies are well-positioned to take advantage of this rapidly growing demand.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Citigroup Inc. increased its stake in shares of Citius Pharmaceuticals by 146.8% in the third quarter. Citigroup Inc. now owns 13,338 shares of the company’s stock worth $27,000 after purchasing an additional 7,934 shares in the last quarter. Royal Bank of Canada purchased a new position in shares of Citius Pharmaceuticals in the second quarter worth about $27,000. Legal & General Group Plc purchased a new position in shares of Citius Pharmaceuticals in the second quarter worth about $32,000. BNP Paribas Arbitrage SA bought a new position in shares of Citius Pharmaceuticals in the second quarter valued at approximately $42,000. Finally, LPL Financial LLC bought a new position in shares of Citius Pharmaceuticals in the third quarter valued at approximately $44,000. 17.20% of the stock is currently owned by institutional investors.
Shares of Citius Pharmaceuticals stock opened at $1.41 on Friday. The company has a 50 day moving average of $1.61 and a 200-day moving average of $1.84. Citius Pharmaceuticals has a 1-year low of $1.16 and a 1-year high of $4.56. The company has a market cap of $205.90 million, a PE ratio of -5.22 and a beta of 1.45.
About Citius Pharmaceuticals
Citius Pharmaceuticals, Inc is a biopharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.
Featured Article: Marijuana Stocks Future Looks Bright
Get a free copy of the Zacks research report on Citius Pharmaceuticals (CTXR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Should you invest $1,000 in Citius Pharmaceuticals right now?
Before you consider Citius Pharmaceuticals, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Citius Pharmaceuticals wasn’t on the list.
While Citius Pharmaceuticals currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here
Be the first to comment